Objective: Stereotactic radiosurgery (SRS) is widely used for the treatment of intracranial dural arteriovenous fistulas (DAVFs); however, the outcomes of repeated SRS to deal with residual DAVFs are unclear. This study assessed the benefits and potential negative consequences of repeated SRS in patients with residual DAVFs. Methods: This retrospective study examined all patients who underwent two SRS procedures for DAVFs in a single academic medical center between January 1998 and December 2022. Information related to patient demography, DAVFs characteristics, and clinical outcomes were obtained from medical records. The objective in this study was to obtain a preliminary overview of the results of repeated SRS for DAVFs. Results: The study cohort of 19 patients included 14 patients with non-cavernous sinus (NCS) DAVFs and 5 patients with cavernous sinus (CS) DAVFs. The NCS group included 8 patients who were categorized as low-grade (Borden grade 1) and 6 as high-grade (Borden grade 2 or 3). The median follow up duration after the second session of SRS was 37 months. Symptomatic improvement was noted in 16 patients (84.2%) and total obliteration was identified in 11 patients (57.9%). No patient suffered from intracranial hemorrhage after the repeated SRS. One patient (5.3%) experienced symptomatic radiation-induced change mandating temporary course of medical treatment. Conclusions: Repeated SRS appears to be a safe and effective approach to deal with residual DAVFs, resulting in symptomatic improvement and complete radiologic obliteration.

Rosette-forming glioneuronal tumors (RGNT) are rare and novel World Health Organization grade I neoplasms that typically arise in the fourth ventricle and progress slowly. Surgical resection is the standard treatment. However, owing to their adherence to critical structures, complete resection is often not possible. The role of stereotactic radiosurgery (SRS) in the management of RGNT remains inconclusive. We present a case of tissue-confirmed RGNT successfully treated with SRS. A 24-year-old woman presented with diplopia and dysequilibrium and was subsequently diagnosed with a fourth ventricular tumor. Subtotal resection was performed at another hospital, and a tissue-based diagnosis of RGNT was made. After a multidisciplinary discussion and following the patient’s willingness, single-session SRS was prescribed at a marginal dose of 12 Gy. During the subsequent 66-month follow-up period, radiologic regression of the tumor with corresponding resolution of symptoms was noted. She remained neurologically intact at her last official visit. The treatment paradigm for residual RGNT remains elusive due to its scarcity and varied presentation. We have presented our preliminary experience with a residual RGNT that was managed with SRS, attaining long-term freedom from tumor progression. SRS may be a safe, effective, and durable treatment modality for patients with RGNT.

Radiosurgery is a minimally invasive therapy for intractable classical trigeminal neuralgia (TN) with favorable outcomes. However, a little of studies have